Challenge
A late-stage clinical biopharma company needed support to develop a global market access strategy for its cardiology rare disease asset. They wanted to conduct a pricing and access analogue assessment to determine an appropriate access and pricing strategy.
Approach
Scimitar reviewed pre-existing research across opportunity assessment, pricing, and brand strategic plans to determine criteria for assessment. We leverage the content to collaborate with internal stakeholders to create country-specific launch plans and access roadmaps.
Impact
Generated deliverables contributed to key actions and timing to execute reimbursement strategy and launch planning efforts.